Media coverage about Fluidigm (NASDAQ:FLDM) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Fluidigm earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.1853139472863 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of FLDM stock traded up $0.21 during trading on Wednesday, reaching $6.51. The company had a trading volume of 155,305 shares, compared to its average volume of 214,955. The company has a market capitalization of $245.68, a price-to-earnings ratio of -3.43 and a beta of 2.97. Fluidigm has a 1-year low of $2.52 and a 1-year high of $8.38. The company has a quick ratio of 2.38, a current ratio of 2.83 and a debt-to-equity ratio of 6.31.
Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $27.75 million for the quarter, compared to the consensus estimate of $27.14 million. Fluidigm had a negative return on equity of 118.56% and a negative net margin of 59.38%. The business’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) earnings per share. research analysts anticipate that Fluidigm will post -0.93 EPS for the current fiscal year.
In other Fluidigm news, insider Levin Capital Strategies, L.P. purchased 11,230 shares of the company’s stock in a transaction that occurred on Friday, December 29th. The shares were acquired at an average cost of $5.94 per share, for a total transaction of $66,706.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 726,016 shares of company stock worth $4,515,007 over the last quarter. 4.70% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Fluidigm (NASDAQ:FLDM) Share Price” was posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://baseballnewssource.com/2018/03/21/fluidigm-fldm-given-daily-media-impact-score-of-0-22/1923797.html.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.